Patrick Tobbia, MD
Interventional Cardiology · Little Rock, ARNPI 1427362011
Payments from drug & device makers
Across 350 payments — averaging $38.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$4K
- Boston Scientific$2K
- Medtronic$2K
- Abbott$1K
- W. L. Gore & Associates, Inc.$1K
- Abiomed$545
- plus $3K from 30 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Travel & lodging$5,79143%
- Food & beverage$7,69157%
- Education$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 38 | $3,813 |
| Boston Scientific | 46 | $1,752 |
| Medtronic | 24 | $1,620 |
| Abbott | 37 | $1,500 |
| W. L. Gore & Associates, Inc. | 13 | $1,381 |
| Abiomed | 18 | $545 |
| Novartis | 24 | $400 |
| Shockwave Medical, Inc | 19 | $349 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $307 |
| Pfizer | 13 | $223 |
| Bard Peripheral Vascular, Inc. | 9 | $204 |
| Merck | 11 | $182 |
| Amgen | 9 | $123 |
| Novo Nordisk | 6 | $120 |
| Astellas Pharma US Inc | 2 | $120 |
| E.r. Squibb & Sons, L.L.C. | 8 | $119 |
| AstraZeneca | 8 | $110 |
| Philips North America LLC | 6 | $98 |
| Cardiva Medical, Inc. | 2 | $87 |
| Asahi Intecc USA, Inc. | 5 | $86 |
| Johnson & Johnson | 5 | $83 |
| Baxter Healthcare | 2 | $42 |
| Scpharmaceuticals Inc. | 2 | $39 |
| Gilead | 3 | $38 |
| Elutia, Inc. | 2 | $34 |
| Bardy Diagnostics, Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Avinger Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Teleflex LLC | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Heartflow, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,603 in reported general payments places this provider in the 70th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,071 | $973,350 |
| EntrestoSacubitril/Valsartan | 234 | $243,412 |
| XareltoRivaroxaban | 141 | $126,216 |
| JardianceEmpagliflozin | 127 | $114,987 |
| Repatha SureclickEvolocumab | 114 | $84,144 |
| BrilintaTicagrelor | 121 | $82,180 |
| FarxigaDapagliflozin Propanediol | 122 | $80,345 |
| MounjaroTirzepatide | 65 | $76,993 |
| MultaqDronedarone Hcl | 44 | $45,954 |
| WegovySemaglutide | 31 | $40,421 |
| Ranolazine ErRanolazine | 386 | $35,551 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 1,533 | $33,597 |
| Bisoprolol Fumarate | 1,071 | $27,893 |
| Repatha SyringeEvolocumab | 48 | $27,040 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 84 | $16,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $223 | $973,3501,071 claims |
| NovartisEntresto | $400 | $243,412234 claims |
| AstraZenecaBrilinta, Farxiga | $110 | $162,525243 claims |
| Johnson & JohnsonXarelto | $83 | $126,216141 claims |
| Boehringer IngelheimJardiance | $13 | $114,987127 claims |
| Novo NordiskWegovy, Ozempic | $120 | $54,43646 claims |
| Sanofi-aventis U.S. LLCMultaq | $26 | $45,95444 claims |
| MerckVerquvo | $182 | $8,76113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Little Rock
- Gaurav DharLittle Rock$793K
- Ernesto Ruiz-RodriguezLittle Rock$499K
- Vasili LendelLittle Rock$206K
- Vijay RajaLittle Rock$106K
- Thomas WattsLittle Rock$79K
- Stephen BroughtonLittle Rock$34K
- Mahesh Anantha NarayananLittle Rock$26K
- Aravind RaoLittle Rock$17K
- Subhi AlarefLittle Rock$13K
- Hamza RayesLittle Rock$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.